Member Info for CHELSEA7

Not a case of being happy Inan, you know very well my views on a couple of posters here, I just happened to share your view about that particular comment, but i just gave my opinion on how I see it, not how i see the poster. Simples.

This is such a shame. Such a good BB yesterday and it is not just my opinion that Bermudas input is so very valuable to us, as is yours, but these petty rows as I said yesterday are keeping numerous good posters away from this BB in droves.

Please take it back to the ADVFN BB

Ruck,

Ha ha, yeah i got that in the wee hours. It was a shame how the AGM worked out in the end, a few of us were planning on meeting up for some time, a couple couldn"t attend because of holiday arrangements, expecting an October AGM, and three of us changed our plans at the very last minute. Unfortunately the person taking me had to leave immediately after it ended, which made it pretty pointless for me to go as I wanted time to have a chat and also had a couple of questions for CH and MD. Was surprised only 24 people attended though, I think you said?

Morning Bermuda, yes I understand that very well, but as far as the commercial side goes, we have probably been in numerous discussions as to what should be acceptable for commercial deals. I choose to believe that Scancell have not been told that a 25 patient trial would be insufficient, otherwise why the heck do it. I know you understand this,that the Vulpes investment is a commercial deal, by way of monetising assets, but as you have probably noticed I am challenging some posts that by there very nature suggest the BOD are ""inept"" quote, and by definition stupid.

I must add that since the BOD has been strengthened IMHO by the addition of Vulpes, which should have quelled some of the doubters who felt we are incapable of negotiating any kind of commercial deal, I feel a lot more comfortable in my investment than I have for some time and yes I do trust the BOD to see through a very clear stratagy for future success. Mindful that it is not a foregone conclusion, funding will always be an issue until we start receiving an income, but with Vulpes on board I feel we could be very well positioned to secure a wder range of solutions than what we have seen before.

Morning,

Funny you should post that Inanaco, i"ve been up all night and was thinking of Bermudas post. The SP even back in 2016 was 12.5-15p which suggests forgetting this price, it was never a realistic sum to raise even back then.

Makes me wonder back then whether there was a realistic chance of getting a partner to see us through such a large study, which could well have fallen through by the delays to manufacturing a new batch of SCIB1 and later the Tri Grid delays?? In any case you gave an example of a 28 patient trial, and TBH I have seen numerous studies of 30 or less patients.

You would have thought also after many meetings with potential partners, and even taking the advice of people of the calibre of Keith Flaherty, it was clear to Scancell that a trial of 25 patients would be sufficient for purpose and with hopefully data above expected norms would be sufficient for any potential future partners?

Ruck,

????

Night buddy

Well something we shouldn"t underestimate is many eyes from the Oncology world will be looking for results from this trial, compared to the awareness we had at the time of the SCIB1 mono trial, even taking account the U.S. arm is not taking place at least for now. I was rather misquoted the other day on my view of that, given the circumstances as to why, although still a bit sketchy I am just delighted we are going ahead with the U.K. arm with no further delay.

No need for me to justify what was twisted to suit, I just don"t see any point in dwelling on will not be happening. I f anything does change there is still time as we go to re apply for that IND, I have no idea whether that is the BODs intention though...Just wanted to remind us that our buyer/s is certainly back, even omitting the 103k buy being probably a PI buy, there were another 800k bought last week on very low volumes, 2 x 250k buys and 3 x 100k buys, and it seemed as if the MMs were working overtime to find a seller. Will be interesting how that pans out next week, but yes another £58k spent building a stake, after for many weeks adding 1m shares a week at this level. Well done holders for making them work hard, so few sells, we are holding tight. We even saw the bid rise from 6.80 to 7.1175, not bad for a quiet week.

So to next week, .............

And on that point of funding I thought Bermuda, again, made an excellent point.................."".Regarding SCIB1, if the trial is successful then it needs to move into a much larger randomised study and the concern must be whether the results in just 25 patients will be enough to attract a partner to fund it. That's a very different risk though from whether or not the market has disappeared because others have beaten Scancell to it."""

I suppose the term ""Big Pharma"" sounds like the ultimate goal for Scancell, been trying to find the actual words used by Chiplin three years ago, saying to effect we were targetting second tier Big Pharma"", not the actual words used but there is a huge market that exists behind the biggest names where our science is of maybe greater interest, BioNTech is one, our collaborator on the third platform another and we will only grt to hear of others when a collaboration or commercial deal is completed.

We had that situation with RG when he was retiring when frustration over his "failures" were high, and then received a few rNS s in quick succession over collaborations he had negotiated with ISA Pharmaceuticals, Amplivant etc again all situations that couldn"t be discussed prior to when they were.

The reason I have enjoyed the posts today is simply they have all been constructive, iit is not criticism I fight, I well get that linked to expectations and frustration, but I just feel we have so much to discuss of how Scancell have put us in a much stronger position, and thanks Ray for your thoughts on two CIs, why three might be one too many and how SCIB1 could jut be the answer along with many others.

There are five holders who I enjoy being in contact with, long term Scancell holders who like me are holding tight and looking for trading opportunities too, they have lowered their averages enormously in the City Financial ""sale"", and whilst they post rarely it is so good to hear honest opinions. Everybody is so realistic about our prospects, taking into account how nothing is a given, so the opinions are not from blind adoration but valued opinions. I look forward to them all re joining us here, good news and that move back to double figures will do it, and most importantly a continuation of the atmosphere so well on view for all to see today.

I just feel many of the plans we have fror the coming year are a result of numerous meetings with prospective deal makers, I too would love to see 75 man trials, but we work under strict financial constraints, I just have confidence in this BOD to get there in the end, i do feel some of the criticism aimed at them is frustration, but the day I feel I know better than them and Lindy, and disagree how we are going about it, will be the day I sell my shares. For now, that is far from the case.

And Dracula your post recommended. Apart the financial constraints and human resources we have had to work with, we have come a long way in the last few years. Just IMHO and I understand many are unsure abiut Chiplin, it was he came along at a crossroads period and put in place a stratagy, which the BOD knew would take 3 years at least to be ready to move forward. 23 staff now, 12 of whom are PhDs, Smantha Paston a tremendous appointment which we will see in the coing years from the work she is doing.

I couldn"t have disagreed more with the comments of becomimg obsolete, and have learned to realise just how difficult funding can be to get, it is my hope with Vulpes on board future funding needs will be handled very differently.

Luck is another componant, something we have all needed in past and current ventures, and I don"t feel in that respect we have been blessed with it. I am genuinly happy to hold, if I wasn"t I would sell for a 50% loss, get back £16k, which fortunately I don"t need to have just now.

Something I wanted to put to you all was our current financial position. I posted it last week and was delighted it was about £3m higher than I thought, and the BOD have confirmed we are funded until early 2021. MOD1 is scheduled for H1 2020 a timeline i pray we can meet, considering we are funded for the Combo Trial, not sure exactly how many patients for, but if we do start MOD1 on time how will that be funded??? Doesn"t add up in my equations, any ideas guys???

A few of us commented before Vulpes took their stake that the BOD seemed to know where the next monies were coming from, well they did, Vulpes, and i get the same feeling now, it is just we are ok to 2021 but the MOD1 is mid 2020 are we expecting a commercial deal berore that??

""But Ruck, there is no race with one overall winner - it just doesn't work like that."""

It really doesn"t work like that and so much has improved in the last six years, but we are still looking for kinder treatments, so many patients fall into a catagory where all available treatments are beyond what a patients health can sustain, there are still so many types of cancer which are untreatable, and even Keytruda seems to be a suitable treatment for just 20% of patients, and just look what a financial success story that has proved to be. With the help of diagnostics and sequencing we will see improved overall survival data.

Perhaps also with a few years of data from combination trials, results from our SCIB1 trial could be seen to be well above established norms.

Financing is always a concern for all Biotechs, and I just wonder what value the market would rate us at if we could reach just £10m a year for starters in licensing deals across all three platforms??? And yes dragon that Vulpes investment after so much research and due diligence makes you think.

Anyway it is that time of year again, to wish everybody here a Happy and Healthy Jewish New Year, I left out wealthy, lol, as it really does come last.

Night you guys, great posts.

A far better link.......................

ipilimumab - Opdivo

https://www.opdivo.com › how-the-combination-works-combinationtherapy
Learn how OPDIVO® (nivolumab) + YERVOY® (ipilimumab) works with your immune system. .

Ipilimumab (Yervoy) | Cancer information | Cancer Research UK

https://www.cancerresearchuk.org › treatment › cancer-drugs › drugs › ipil...
4 Sep 2019 - Ipilimumab is a type of cancer treatment called immunotherapy. ... Ipilimumab works by blocking a protein that stops your immune system from working properly and attacking cancer cells. ... If you are having ipilimumab for melanoma or kidney cancer you might have it with another type of ...

Nivolumab, marketed as Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have ... Wikipedia

Have a good day

Which is Opvido/ Yervoy to us mere mortals.

Buys 176k

Sells 320k

Have a good weekend guys

The buy at 7.25 presumably.

14:49:33 7.10 150,000 10.65k O
14:38:40 7.295 54,832 4,000

Well they found a seller after yesterdays blitz..............

Buys 76k

Sells 320k

Up to 50k 7.1145

51k-120k 7.10

And a buy over on NEX....27/09/2019 14:39 20,632 7.27......................spread now 2%!!

7.295

Somethings on for after 4, IMHO................catch yer later

120k at 7.10